← Leaderboards
Cory Abate-Shen
Columbia University Health Sciences
$42,493,197
Attributed
$43,389,598
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,236,052 · 18
By mechanism
R01$24,087,445 · 10
P01$14,448,977 · 5
U01$13,408,717 · 2
P30$4,290,913 · 1
Top collaborators
- Michael M. Shen3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Wei Gu$36,684,013
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMalignant NeoplasmsMalignant Neoplasm Of ProstateInvestigationMouse ModelGenetically Engineered MouseIn VivoGenesTumorBaseInsightPathway InteractionsPhenotypeLoss Of FunctionCellsTumor ProgressionTissuesProgramsCessation Of LifeInnovationSeriesProstateNeoplasm MetastasisResponse
Grant awards (111)
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$575,750
R01 · FY2025 · CA · contact PI
Nuclear and non-nuclear functions of NKX3.1 in suppression of prostate cancer$546,133
R01 · FY2025 · CA · contact PI
Investigating mechanisms of bladder cancer metastasis$516,846
R01 · FY2025 · CA · contact PI
Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis$491,936
P01 · FY2025 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$473,852
R01 · FY2025 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$546,963
R01 · FY2024 · CA · contact PI
Investigating mechanisms of bladder cancer metastasis$516,846
R01 · FY2024 · CA · contact PI
Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis$462,982
P01 · FY2024 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$450,160
R01 · FY2024 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$575,750
R01 · FY2023 · CA · contact PI
Investigating mechanisms of bladder cancer metastasis$516,846
R01 · FY2023 · CA · contact PI
Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis$473,522
P01 · FY2023 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$464,375
R01 · FY2023 · CA · contact PI
Mitochondrial and nuclear functions of NKX3.1 in regulating oxidative stress in prostate cancer$379,343
R01 · FY2023 · CA · contact PI
Modeling bladder cancer pathogenesis and tumor evolution$1,684,618
P01 · FY2022 · CA · contact PI
Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis$639,074
P01 · FY2022 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$464,375
R01 · FY2022 · CA · contact PI
Mitochondrial and nuclear functions of NKX3.1 in regulating oxidative stress in prostate cancer$379,343
R01 · FY2022 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$378,165
R01 · FY2022 · CA · contact PI
Project 2: Functions of ARID1A in muscle invasive bladder cancer$288,986
P01 · FY2022 · CA · contact PI
Core C: Administrative Core$158,637
P01 · FY2022 · CA · contact PI
Modeling bladder cancer pathogenesis and tumor evolution$1,718,998
P01 · FY2021 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$473,850
R01 · FY2021 · CA · contact PI
Mitochondrial and nuclear functions of NKX3.1 in regulating oxidative stress in prostate cancer$387,084
R01 · FY2021 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$385,883
R01 · FY2021 · CA · contact PI
Project 2: Functions of ARID1A in muscle invasive bladder cancer$369,765
P01 · FY2021 · CA · contact PI
Core C: Administrative Core$136,476
P01 · FY2021 · CA · contact PI
Modeling bladder cancer pathogenesis and tumor evolution$1,718,998
P01 · FY2020 · CA · contact PI
Mitochondrial and nuclear functions of NKX3.1 in regulating oxidative stress in prostate cancer$387,084
R01 · FY2020 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$385,883
R01 · FY2020 · CA · contact PI
Project 2: Functions of ARID1A in muscle invasive bladder cancer$369,765
P01 · FY2020 · CA · contact PI
Core C: Administrative Core$136,476
P01 · FY2020 · CA · contact PI
Modeling bladder cancer pathogenesis and tumor evolution$1,667,429
P01 · FY2019 · CA · contact PI
Investigating the cell of origin for bladder cancer$460,530
R01 · FY2019 · CA · contact PI
Mitochondrial and nuclear functions of NKX3.1 in regulating oxidative stress in prostate cancer$387,084
R01 · FY2019 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$374,307
R01 · FY2019 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$355,019
R01 · FY2019 · CA · contact PI
Project 2: Functions of ARID1A in muscle invasive bladder cancer$286,121
P01 · FY2019 · CA · contact PI
Core C: Administrative Core$155,772
P01 · FY2019 · CA · contact PI
Modeling bladder cancer pathogenesis and tumor evolution$1,765,498
P01 · FY2018 · CA · contact PI
Analysis of drug response in organoids and mouse models$597,601
R01 · FY2018 · CA
Investigating the cell of origin for bladder cancer$474,774
R01 · FY2018 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$385,883
R01 · FY2018 · CA · contact PI
Project 2: Functions of ARID1A in muscle invasive bladder cancer$369,765
P01 · FY2018 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$366,000
R01 · FY2018 · CA · contact PI
Core C: Administrative Core$151,976
P01 · FY2018 · CA · contact PI
Cancer Center Support Grant$3,792,720
P30 · FY2017 · CA · contact PI
Analysis of drug response in organoids and mouse models$597,601
R01 · FY2017 · CA
Investigating the cell of origin for bladder cancer$474,774
R01 · FY2017 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$389,781
R01 · FY2017 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$366,000
R01 · FY2017 · CA · contact PI
Cancer Center Support Grant$199,541
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$120,000
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$118,652
P30 · FY2017 · CA · contact PI
Cancer Center Support Grant$60,000
P30 · FY2017 · CA · contact PI
Analysis of drug response in organoids and mouse models$597,601
R01 · FY2016 · CA
Investigating the cell of origin for bladder cancer$474,774
R01 · FY2016 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$389,781
R01 · FY2016 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$366,000
R01 · FY2016 · CA · contact PI
Investigating the cell of origin for bladder cancer$474,774
R01 · FY2015 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$389,781
R01 · FY2015 · CA · contact PI
Molecular mechanisms of prostate cancer metastasis$366,000
R01 · FY2015 · CA · contact PI
Roles for Nkx3.1 in Prostate Cancer Initiation$354,926
P01 · FY2015 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$378,088
R01 · FY2014 · CA · contact PI
Roles for Nkx3.1 in Prostate Cancer Initiation$348,035
P01 · FY2014 · CA · contact PI
Elucidation of cancer pathways and druggable targets using mouse models.$685,776
U01 · FY2013 · CA · contact PI
Preclinical analyses of advanced prostate cancer in genetically-engineered mice$389,781
R01 · FY2013 · CA · contact PI
Leadership Component in Chemoprevention: Mouse Models of Human Cancer Consortium$377,353
U01 · FY2013 · CA · contact PI
Roles for Nkx3.1 in Prostate Cancer Initiation$341,107
P01 · FY2013 · CA · contact PI
Elucidation of cancer pathways and druggable targets using mouse models.$753,359
U01 · FY2012 · CA · contact PI
Leadership Component in Chemoprevention: Mouse Models of Human Cancer Consortium$375,333
U01 · FY2012 · CA · contact PI
Roles for Nkx3.1 in Prostate Cancer Initiation$358,115
P01 · FY2012 · CA · contact PI
Elucidation of cancer pathways and druggable targets using mouse models.$873,915
U01 · FY2011 · CA · contact PI
Leadership Component in Chemoprevention: Mouse Models of Human Cancer Consortium$402,325
U01 · FY2011 · CA · contact PI
Modeling androgen-independent prostate cancer in mutant mice$296,723
R01 · FY2011 · CA · contact PI
Elucidation of cancer pathways and druggable targets using mouse models.$729,463
U01 · FY2010 · CA · contact PI
Leadership Component in Chemoprevention: Mouse Models of Human Cancer Consortium$415,242
U01 · FY2010 · CA · contact PI
Modeling androgen-independent prostate cancer in mutant mice$305,900
R01 · FY2010 · CA · contact PI
Elucidation of cancer pathways and druggable targets using mouse models.$835,000
U01 · FY2009 · CA · contact PI
Leadership Component in Chemoprevention: Mouse Models of Human Cancer Consortium$410,000
U01 · FY2009 · CA · contact PI
Modeling androgen-independent prostate cancer in mutant mice$305,900
R01 · FY2009 · CA · contact PI
A Mouse Model for Prostate Cancer$1,446,104
U01 · FY2008 · CA · contact PI
Modeling androgen-independent prostate cancer in mutant mice$305,900
R01 · FY2008 · CA · contact PI
A Mouse Model for Prostate Cancer$1,212,233
U01 · FY2007 · CA · contact PI
Modeling androgen-independent prostate cancer in mutant mice$293,554
R01 · FY2007 · CA · contact PI
Roles of Nkx3.1 in prostate development and cancer$231,840
R01 · FY2007 · CA · contact PI
Roles for MSX1 in vertebrate embryogenesis$176,710
R01 · FY2007 · HD · contact PI
Roles for MSX1 in vertebrate embryogenesis$146,170
R01 · FY2007 · HD · contact PI
Roles of Nkx3.1 in prostate development and cancer$87,921
R01 · FY2007 · CA · contact PI
A Mouse Model for Prostate Cancer$1,070,817
U01 · FY2006 · CA · contact PI
Roles for MSX1 in vertebrate embryogenesis$332,875
R01 · FY2006 · HD · contact PI
Roles of Nkx3.1 in prostate development and cancer$321,154
R01 · FY2006 · CA · contact PI
A Mouse Model for Prostate Cancer$986,802
U01 · FY2005 · CA
Roles for MSX1 in vertebrate embryogenesis$341,231
R01 · FY2005 · HD
Roles of Nkx3.1 in prostate development and cancer$328,883
R01 · FY2005 · CA
A Mouse Model for Prostate Cancer$849,196
U01 · FY2004 · CA
Roles for MSX1 in vertebrate embryogenesis$341,563
R01 · FY2004 · HD
Roles of Nkx3.1 in prostate development and cancer$328,883
R01 · FY2004 · CA
A MOUSE MODEL FOR PROSTATE CANCER$513,125
U01 · FY2003 · CA
Roles of Nkx3.1 in prostate development and cancer$328,883
R01 · FY2003 · CA
Roles for MSX1 in vertebrate embryogenesis$227,922
R01 · FY2003 · HD
A MOUSE MODEL FOR PROSTATE CANCER$498,535
U01 · FY2002 · CA
NKX31 AND PROSTATE DEVELOPMENT AND CANCER$268,530
R01 · FY2002 · CA
MSXL (HOX 7.1) IN MURINE EMBRYOGENESIS$172,616
R01 · FY2002 · HD
A MOUSE MODEL FOR PROSTATE CANCER$484,325
U01 · FY2001 · CA
NKX31 AND PROSTATE DEVELOPMENT AND CANCER$261,627
R01 · FY2001 · CA
MSXL (HOX 7.1) IN MURINE EMBRYOGENESIS$251,567
R01 · FY2001 · HD
A MOUSE MODEL FOR PROSTATE CANCER$470,221
U01 · FY2000 · CA
NKX31 AND PROSTATE DEVELOPMENT AND CANCER$326,476
R01 · FY2000 · CA
MSXL (HOX 7.1) IN MURINE EMBRYOGENESIS$244,152
R01 · FY2000 · HD
A MOUSE MODEL FOR PROSTATE CANCER$19,593
U01 · FY2000 · CA